Conciliating biosafety with efficient gene transfer remains a constant concern in the development of retroviral vectors. Semliki Forest virus (SFV) replicons allow important retroviral vector production with interesting features. It is noteworthy that retroviruses have the ability to package ⌿ ؉ and, to some extent, ⌿ ؊ cellular RNAs. Therefore, it was important to study the retroviral transfer of highly abundant SFV genomes expressing retroviral proteins. Here, we show that full-length SFV-vector replicons, with or without ⌿, are efficiently packaged into retrovirus particles. Mechanistically, our data suggest that SFV packaging is the sum of its retroviral nucleocapsid-dependent recruitment together with a passive hijacking of membrane-anchored SFV replicon. A direct consequence of this phenomenon is the formation of particles harboring autonomous replicative abilities and contaminating vector preparations. Importantly, we confirm that retroviral SFV mobilization is not an exclusive feature of murine gamma retroviruses, since it is also observed using lentivectors.It is well established that retroviral vectors derived from simple oncoretroviruses, murine leukemia virus (MLV), or lentiviruses, such as human immunodeficiency virus type 1 (HIV-1), are effective and versatile gene delivery systems (31). Recombinant particle production involves the expression of two components, either continuously in stable packaging cell lines or transiently by cotransfection of naïve cells (31). Vector production by stable cell lines can be maximized using bioreactors or various chemical boosts (4,14,23,26,32). Most transient production protocols rely on DNA transfection, with the rest involving delivery of retroviral components using heterologous viral vectors (20,31,38,40,43,44). Among these is the Semliki Forest virus (SFV) vector system (20, 43). It was initially developed for robust protein production in mammalian cells (1). SFV-positive RNA is capable of autoamplification through self-primed replication (42). In addition, the SFV genome contains an internal promoter, which prompts a further amplification via transcription of a subgenomic RNA (42). Within vectors, the subgenomic RNA encodes the transgene (25). Li and Garoff and others have developed an SFV system allowing retroviral vector production (20, 43). Interestingly, Li and collaborators have shown that the Semliki-derived system, which displays an exclusive cytoplasmic replication, allows the transfer of intron-containing retroviral vectors (19).An important consideration when using retroviral vectors as therapeutic tools is biosafety (31). Treatment of severe combined immunodeficiency (SCID) patients has emphasized the risk of insertional mutagenesis with retroviral vector based on MLV (12). As a consequence, targeted integration is now a major goal (2). Replication-competent retrovirus (RCR) in vector preparations is also to be considered. In animal models, RCRs have been shown to trigger cancer (3, 13, 24). Using classical retroviral production systems, the emerg...